STUDresearch · Non-peptide
TAK-653
Also known as
osavampator · TAK653 · TAK 653 · AMPA PAM TAK-653
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Cognitive research compounds
Systemic oral AMPA receptor positive allosteric modulator.
What people say
An investigational oral AMPA-receptor positive allosteric modulator also called osavampator, originally developed in a depression program and discussed online as a nootropic. It is not a peptide or stimulant prescription.
Doses people talk about
Rows are reported study or community amounts, not a progression. Product identity, psychiatric history and co-stimulants matter.
How it may feel
Reports range from improved focus, retention or quieter thinking to no effect, head pressure, irritability, mistakes, emotional blunting or activation. Same-author updates sometimes changed after dose changes, but remain uncontrolled.
Common forum amount2 mg orally once daily
Frequently named in nootropic posts and vendor-adjacent discussion; not clinically validated for cognition.
Long-term individual report2.5 mg orally once daily
Roughly two-year self-report with bipolar and mood-stabilizing medication context; not a controlled or validated long-term dose.
High-dose forum caution8 mg orally in a secondhand report
Amount associated with a relayed mania story; not a proven threshold, safe band or direct first-person study result.
CNS phase 1 single doses0.5, 3, or 6 mg orally once
Three crossover-study amounts in healthy volunteers; not a daily consumer range.
Half-life & effect duration
- Half-life in the body
- Reported human study rangeAbout 33.1–47.8 hours
- Felt duration people report
- Positive accountsAll-day effects or changes across several days
- Other accountsNo effect, or head pressure that changed after lowering the amount
Cycles people discuss
Forums describe daily or short test blocks. One author reported about two years at 2.5 mg daily while also describing bipolar and mood-stabilizing medication context; that does not establish a validated schedule or long-term safety.
Timing
Morning use alongside other nootropics appears in the retained forum notes. Same-day sleep or dream changes are also reported; these accounts do not establish a preferred meal window or a validated timing rule.
Stacks
Cerebrolysin, wakefulness agents and other nootropics appear in screenshots and reports, but commercial promotion and multi-agent use make attribution poor; no combination is established.
Watch for
Activation / mania reports: A vendor-adjacent author described overstimulation or hypomania above 3 mg and relayed another person’s mania at 8 mg. Separate long-term and short-term posts include bipolar context, irritability or emotional blunting; no dose threshold is established.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A peer-reviewed human CNS paper cites a 33.1–47.8-hour plasma half-life from an earlier phase 1 conference abstract.
The inspected crossover CNS study gave single oral 0.5, 3 and 6 mg doses to 24 healthy volunteers. Its introduction cites the half-life range; ClinicalTrials.gov posts other PK outcomes but not half-life.
The primary conference abstract/table was not directly retrievable in the inspected record, so this is a traceable secondary report, not independently checked raw PK data.
- Effects of the AMPA receptor potentiator TAK-653 on human brain activity (opens in a new tab)Methods: 24 healthy volunteers received single oral 0.5, 3 and 6 mg doses in a crossover design with 10–15-day washouts. Introduction cites 33.1–47.8-hour half-life from a phase 1 conference abstract.CNS pharmacodynamic study; cited half-life is secondary to an abstract not directly reproduced as a PK table.
- ClinicalTrials.gov NCT02561156 results (opens in a new tab)Posted study arms and pharmacokinetic outcome tables for single 0.3–18 mg and repeated 0.3–9 mg oral dosing were inspected; half-life was not a posted outcome.Registry results are not a substitute for the unavailable conference-abstract half-life table.
Felt duration people report
No dependable felt-duration clock: reports include all-day effects, changes over several days, no effect and adverse sensations that changed after lowering the amount.
One four-day 1 mg reporter later said head pressure resolved at 0.5 mg while benefits remained. Other authors described three-day, long-term or vendor-adjacent experiences with different products and stacks.
Self-selected reports, unverified compounds, commercial conflicts, psychiatric and medication confounders, and no blinded attribution. No prevalence can be inferred.
- TAK-653 head-pressure report and same-author update (opens in a new tab)Original four-day 1 mg report described focus/retention plus head pressure, mistakes, irritability, headache and vivid dreams; same-author update said pressure resolved after lowering to 0.5 mg while perceived benefits remained.Single uncontrolled account, unverified product and short follow-up; lowering amount and improvement do not prove causation.
- TAK-653 experience and cognitive-test discussion (opens in a new tab)Original post, author comments and replies describing 2 mg preference, all-day effects, cognitive-test claims, overstimulation/hypomania above 3 mg, a relayed 8 mg mania report, vivid dreams and multiple co-products.Author disclosed bringing the product to the community; promotional conflict, unverified testing and multi-agent stacks limit every inference.
- Long-term TAK-653 users discussion (opens in a new tab)Original author reported roughly two years at 2.5 mg once daily, bipolar history and mood-stabilizing medication context; the same-author May follow-up on sleep/side effects and replies with differing activation experiences were also inspected.Unverified product, self-reported bipolar and mood-stabilizing medication context, no objective longitudinal testing and multiple authors.
- Three-day TAK-653 experience discussion (opens in a new tab)Original three-day 2 mg noon report describing quieter thinking, slight anxiolysis, emotional blunting and dampened ambition, plus replies discussing other combinations.Very short uncontrolled exposure; product identity and co-use are uncertain, and replies are not same-author follow-up.
What people say
- Working-memory n=1s: Digit-span posts after acute and week-long 2 mg. Small samples, ceiling effects, website switches — noisy. anecdote
- “I can articulate thoughts” r/NooTopics flavor. forum
- Vivid dreams show up in the same threads. forum
- Not a mood miracle on a forum COA. MDD program ≠ a happiness cap. forum
- Trial cognition signals: Phase 1 bands people cite in the 0.5–6 mg range with some stimulant-like test profiles. Depression efficacy is a separate unfinished story. trial
Doses people talk about
- Stack-screenshot default: 2 mg oral. forum
- High-dose caution in forum lore: A vendor-adjacent discussion relayed another person’s mania at 8 mg, while its main author described overstimulation or hypomania above 3 mg. These are uncontrolled reports, not a defined toxic threshold or working band. anecdote
- Not Semax drops. Different route and molecule. forum
- Trial talk: 0.5–6 mg oral in Phase 1 cognition write-ups. trial
- Framing: Nootropic milligrams and trial arms — not a depression prescription, not a protocol. forum
How it may feel
- Acute to several days: Reports conflict: some describe cleaner focus or quieter thinking, others no clear effect, irritability, pressure, mistakes or emotional blunting. One four-day 1 mg author later reported that head pressure resolved after lowering to 0.5 mg while perceived benefits remained. forum
- Days 1–7: Dream intensity. Occasional edginess. forum
- High-dose reports: A vendor-adjacent author described overstimulation or hypomania above 3 mg and relayed another person’s mania at 8 mg; exact product identity and psychiatric context were not verified. anecdote
- Weed combo: Some said it felt worse. forum
- Stop: No classic racetam dump. Effects are described as on-drug. forum
Cycles people discuss
- Daily-use reports: The preserved notes describe daily use during a cognition experiment rather than an eight-week blast. One forum author reported about two years at 2.5 mg once daily while also describing bipolar and mood-stabilizing medication context; that does not establish safety or a validated schedule. forum
- Week-long test blocks in the digit-span posts. anecdote
- With cerebrolysin pulses: TAK daily, cerebro in IM/IV cycles — two clocks. forum
- Do not treat as a replacement for sleep. forum
Timing
- Oral AMPA PAM — timing in stacks is morning-with-the-nootropics, not a peptide Tmax ritual. forum
- Downstream: Glutamate tone / sleep-dream changes the same day for some; IQ-test lore is a week of daily. forum
- Human half-life report: A peer-reviewed human CNS paper cites a phase 1 conference abstract reporting a 33.1–47.8-hour plasma half-life. The inspected ClinicalTrials.gov results post pharmacokinetic outcomes but not half-life, so the range remains a secondary report rather than directly verified primary-table evidence. trial
- Depression-program titration is not the Reddit 2 mg cap. trial
More on what it is
- Why people talk about it: 2026 stack screenshots put 2 mg next to cerebrolysin, vesugen, tadalafil, armodafinil. r/NooTopics and r/cognitiveTesting keep the n=1s. forum
- Vs Semax / Adamax: Those are nasal peptides. This is an oral AMPA tool from a psych pipeline. forum
- Vs racetams: Same glutamate neighborhood, different molecule. No choline-dump ritual copied here. forum
- Not Adderall. Stimulant-like talk on some trial cognition tests ≠ a Schedule II stack. forum
- What it is: An oral AMPA PAM from a Takeda depression program, now sold into nootropic rooms as osavampator / TAK-653. Swallow. trial
- How it works (plain): Turns AMPA glutamate signaling up a notch (positive allosteric modulator) instead of dumping a stimulant into dopamine. “Limitless pill” YouTube titles oversell that. trial
Stacks
- 2 mg + Cerebrolysin + Vesugen + tadalafil — the 2026 “omnipresence” screenshot. forum
- + Armodafinil in the same photo — stimulant-adjacent, separate legal/feel job. forum
- + Noopept / bromantane / 9-Me-BC on vendor “CNS trio” ads. forum
- Solo 2 mg first if someone actually wants to know which thing is the dream. forum
Storage notes
- Dry caps. Light-tight. forum
- Osavampator vs TAK-653 vs a mystery AMPA on a COA is the identity check. forum
Watch for
- Activation / mania reports: A vendor-adjacent author described overstimulation or hypomania above 3 mg and relayed another person’s mania at 8 mg. Separate long-term and short-term posts include bipolar context, irritability or emotional blunting; no dose threshold is established. anecdote
- Sleep / vivid nightmares. forum
- Not Adderall, still not a toy if someone has bipolar-spectrum talk. forum
- Stack noise with cerebrolysin + a wakefulness agent. forum
- Depression-drug AE table ≠ 2 mg Reddit. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.